Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activation

SRC.5 (SWOG S0502) -- A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors -- was centrally activated 27 February 2009.
http://www.ctg.queensu.ca/trials/sarcoma/src5/src5.html